Scarica l'app Stockscreener
156.57
0.92%
1.43
Dopo l'orario di chiusura:
156.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine Biosciences CCO Eric Benevich sells $333k in stock By Investing.com - Investing.com Australia
Transcript : Neurocrine Biosciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 08 - marketscreener.com
Neurocrine Biosciences at Cantor healthcare conference: growth broadens By Investing.com - Investing.com Canada
Neurocrine Biosciences at Wells Fargo conference: growth story broadens By Investing.com - Investing.com Canada
Officer at Neurocrine (NASDAQ: NBIX) plans 2,154-share sale in 2026 - Stock Titan
Neurocrine Biosciences at Wells Fargo conference: growth story broadens - Investing.com
Neurocrine Biosciences stock rating reaffirmed by RBC Capital - Investing.com Australia
How Advancing NBI-1117567 to Phase 2 and a $10M Milestone Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 36% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Neurocrine Biosciences (NBIX) Stock Could Still Be A Bargain After A 61% Run - simplywall.st
Neurocrine (NBIX) director donates 1,000 shares - Stock Titan
Neurocrine Biosciences Inc. (NBIX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Boston and New York are stops for Neurocrine’s three September healthcare talks. - Stock Titan
Neurocrine Biosciences (NBIX) Institutional Ownership 2026 - MarketBeat
Resilient Neurocrine Biosciences stock holds firm as Crenessity sales surge and valuation stretches - AD HOC NEWS
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go? - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuation - ChartMill
Neurocrine Biosciences (NBIX) Cleared An FDA Milestone, Is It Trading At A Discount? - simplywall.st
How Investors May Respond To Neurocrine Biosciences (NBIX) Phase 4 INGREZZA Patient-Reported Benefit Data - Sahm
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative? - Yahoo Finance
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND - GlobeNewswire
Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run - simplywall.st
Neurocrine Biosciences: 'House Full Of Options' - Seeking Alpha
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Eastern Progress
Zacks Investment ResearchGlobes - Globes - Israel Business News
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data - simplywall.st
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
GlobesIsrael Business News - גלובס
Neurocrine Biosciences Rings the Nasdaq Stock Market Opening Bell - Nasdaq
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance
Neurocrine Biosciences Rings the Opening Bell - Nasdaq
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: 38.54% Potential Upside Beckons Investors - DirectorsTalk Interviews
Neurocrine Biosciences (HAM:NB3) Cyclically Adjusted Price-to-FCF : (As of Aug. 16, 2026) - GuruFocus
S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V. - MarketBeat
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership? - simplywall.st
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Neurocrine Biosciences Inc (NBIX) Shares Fall 3.6% -- What GF Sc - GuruFocus
Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com
Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Yahoo Finance
Neurocrine Biosciences Inc (NBIX) Shares Fall 3.4% -- What GF Sc - GuruFocus
Why is Neurocrine Biosciences stock sliding today? By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) Dips 3%: Stock Holds Above Key Support at $156.99Quality Factor - Vinanet
Why Neurocrine Biosciences (NBIX) Stock Is Down Today - Quiver Quantitative
What's Going On With Neurocrine Biosciences Stock On Wednesday? - Benzinga
Neurocrine down on safety events linked to Vykat (NBIX:NASDAQ) - Seeking Alpha
Neurocrine Biosciences Shares Drop Amid Vykat Safety Reports - StockInvest.us
Neurocrine Biosciences shares fall amid Vykat safety concerns - Yahoo Finance
Neurocrine Biosciences stock falls on Vykat safety concerns By Investing.com - Investing.com Canada
0.73%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):